Chinese herbal preparation xuebijing potently inhibits inflammasome activation in hepatocytes and ameliorates mouse liver ischemia-reperfusion injury

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Liu, Xiqiang ^a   Hu, Zhiqiu ^b   Zhou, Bin ^c   Li, Xiang ^d   Tao, Ran ^a,c  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CASPASE 3; CASPASE 9; CXCL1 CHEMOKINE; CYTOCHROME C; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; HEME OXYGENASE 1; HERBACEOUS AGENT; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; INFLAMMASOME; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; MYOCYTE ENHANCER FACTOR 2; MYOCYTE ENHANCER FACTOR 2C; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; XUEBIJING; REACTIVE OXYGEN METABOLITE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL COUNT; CHINESE MEDICINE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KUPFFER CELL; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER CELL; LIVER FUNCTION TEST; LIVER ISCHEMIA; LIVER RESECTION; LIVER TRANSPLANTATION; MALE; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REPERFUSION INJURY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; LIVER; LIVER DISEASES; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; DRUGS, CHINESE HERBAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPATOCYTES; INFLAMMASOMES; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MICE; MICE, INBRED C57BL; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; REPERFUSION INJURY;

EID: 84940367529     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131436     Document Type: Article

References (55)

1. Wang Y, Shen J, Xiong X, Xu Y, Zhang H, Huang C, et al. (2014) Remote ischemic preconditioning protects against liver ischemia-reperfusion injury via heme oxygenase-1-induced autophagy. PLoS One 9: e98834. doi: 10.1371/journal.pone.0098834 PMID: 24914543
2. Bamboat ZM, Balachandran VP, Ocuin LM, Obaid H, Plitas G, DeMatteo RP(2010) Toll-like receptor 9 inhibition confers protection from liver ischemia-reperfusion injury. Hepatology 51: 621-632. doi: 10. 1002/hep.23365 PMID: 19902481
3. Llacuna L, Mari M, Lluis JM, Garcia-Ruiz C, Fernandez-Checa JC, Morales A (2009) Reactive oxygen species mediate liver injury through parenchymal nuclear factor-kappaB inactivation in prolonged ischemia/reperfusion. Am J Pathol 174: 1776-1785. doi: 10.2353/ajpath.2009.080857 PMID: 19349371
4. Wei L, Ren F, Zhang X, Wen T, Shi H, Zheng S, et al. (2014) Oxidative stress promotes D-GalN/LPSinduced acute hepatotoxicity by increasing glycogen synthase kinase 3beta activity. Inflamm Res 63: 485-494. doi: 10.1007/s00011-014-0720-x PMID: 24531650
5. Sakai N, Van Sweringen HL, Quillin RC, Schuster R, Blanchard J, Burns JM, et al. (2012) Interleukin-33 is hepatoprotective during liver ischemia/reperfusion in mice. Hepatology 56: 1468-1478. doi: 10.1002/hep.25768 PMID: 22782692
6. Ji H, Zhang Y, Shen XD, Gao F, Huang CY, Abad C, et al. (2013) Neuropeptide PACAP in mouse liver ischemia and reperfusion injury: immunomodulation by the cAMP-PKA pathway. Hepatology 57: 1225-1237. doi: 10.1002/hep.25802 PMID: 22532103
7. Ueki S, Castellaneta A, Yoshida O, Ozaki K, Zhang M, Kimura S, et al. (2011) Hepatic B7 homolog 1 expression is essential for controlling cold ischemia/reperfusion injury after mouse liver transplantation. Hepatology 54: 216-228. doi: 10.1002/hep.24360 PMID: 21503939
8. Deng J, Huo D, Wu Q, Zhu L, Liao Y (2013) Xuebijing for paraquat poisoning. Cochrane Database Syst Rev 7: CD010109.
9. Yin Q, Li C (2014) Treatment effects of xuebijing injection in severe septic patients with disseminated intravascular coagulation. Evid Based Complement Alternat Med 2014: 949254. doi: 10.1155/2014/949254 PMID: 24778706
10. Qi F, Liang ZX, She DY, Yan GT, Chen LA (2011) A clinical study on the effects and mechanism of xuebijing injection in severe pneumonia patients. J Tradit Chin Med 31: 46-49. PMID: 21563507
11. Jiang M, Zhou M, Han Y, Xing L, Zhao H, Dong L, et al. (2013) Identification of NF-kappaB Inhibitors in Xuebijing injection for sepsis treatment based on bioactivity-integrated UPLC-Q/TOF. J Ethnopharmacol 147: 426-433. doi: 10.1016/j.jep.2013.03.032 PMID: 23524166
12. Liu MW, Wang YH, Qian CY, Li H (2014) Xuebijing exerts protective effects on lung permeability leakage and lung injury by upregulating Toll-interacting protein expression in rats with sepsis. Int J Mol Med 34: 1492-1504. doi: 10.3892/ijmm.2014.1943 PMID: 25269519
13. Sun J, Xue Q, Guo L, Cui L, Wang J (2010) Xuebijing protects against lipopolysaccharide-induced lung injury in rabbits. Exp Lung Res 36: 211-218. doi: 10.3109/01902140903312123 PMID: 20426529
14. Liu YL, Liu YJ, Liu Y, Li XS, Liu SH, Pan YG, et al. (2014) Hydroxysafflor yellow A ameliorates lipopolysaccharide-induced acute lung injury in mice via modulating toll-like receptor 4 signaling pathways. Int Immunopharmacol 23: 649-657. PMID: 25466274
15. Wang Y, Ji M, Wang L, Chen L, Li J (2014) Xuebijing injection improves the respiratory function in rabbits with oleic acid-induced acute lung injury by inhibiting IL-6 expression and promoting IL-10 expression at the protein and mRNA levels. Exp Ther Med 8: 1593-1598. PMID: 25289065
16. Wang C, Huang Q, Zhu X, Duan Y, Yuan S, Bai X (2013) Hydroxysafflor yellow A suppresses oleic acid-induced acute lung injury via protein kinase A. Toxicol Appl Pharmacol 272: 895-904. doi: 10.1016/j.taap.2013.07.021 PMID: 23933165
17. Wu Y, Wang L, Jin M, Zang BX (2012) Hydroxysafflor yellow A alleviates early inflammatory response of bleomycin-induced mice lung injury. Biol Pharm Bull 35: 515-522. PMID: 22466555
18. Liu MW, Su MX, Wei Z, Yan-Qiong W, Mei C, Li W, et al. (2014) Protective effect of Xuebijing injection on paraquat-induced pulmonary injury via down-regulating the expression of p38 MAPK in rats. BMC Complement Altern Med 14: 498. doi: 10.1186/1472-6882-14-498 PMID: 25511395
19. Qi Z, Yan F, Shi W, Zhang C, Dong W, Zhao Y, et al. (2014) AKT-related autophagy contributes to the neuroprotective efficacy of hydroxysafflor yellow A against ischemic stroke in rats. Transl Stroke Res 5: 501-509. doi: 10.1007/s12975-014-0346-x PMID: 24804941
20. Chen L, Xiang Y, Kong L, Zhang X, Sun B, Wei X, et al. (2013) Hydroxysafflor yellow A protects against cerebral ischemia-reperfusion injury by anti-apoptotic effect through PI3K/Akt/GSK3beta pathway in rat. Neurochem Res 38: 2268-2275. doi: 10.1007/s11064-013-1135-8 PMID: 23990223
21. Han B, Hu J, Shen J, Gao Y, Lu Y, Wang T, et al. (2013) Neuroprotective effect of hydroxysafflor yellow A on 6-hydroxydopamine-induced Parkinson's disease in rats. Eur J Pharmacol 714: 83-88. doi: 10.1016/j.ejphar.2013.06.011 PMID: 23791614
22. Zhang ZH, Yu LJ, Hui XC, Wu ZZ, Yin KL, Yang H, et al. (2014) Hydroxy-safflor yellow A attenuates Abeta(1)(-)(4)(2)-induced inflammation by modulating the JAK2/STAT3/NF-kappaB pathway. Brain Res 1563: 72-80. doi: 10.1016/j.brainres.2014.03.036 PMID: 24690200
23. Liu SX, Zhang Y, Wang YF, Li XC, Xiang MX, Bian C, et al. (2012) Upregulation of heme oxygenase-1 expression by hydroxysafflor yellow A conferring protection from anoxia/reoxygenation-induced apoptosis in H9c2 cardiomyocytes. Int J Cardiol 160: 95-101. doi: 10.1016/j.ijcard.2011.03.033 PMID: 21497407
24. Li D, Lu L, Zhang J, Wang X, Xing Y, Wu H, et al. (2014) Mitigating the effects of Xuebijing injection on hematopoietic cell injury induced by total body irradiation with gamma rays by decreasing reactive oxygen species levels. Int J Mol Sci 15: 10541-10553. doi: 10.3390/ijms150610541 PMID: 24927144
25. Zhang Y, Guo J, Dong H, Zhao X, Zhou L, Li X, et al. (2011) Hydroxysafflor yellow A protects against chronic carbon tetrachloride-induced liver fibrosis. Eur J Pharmacol 660: 438-444. doi: 10.1016/j.ejphar.2011.04.015 PMID: 21536026
26. Wang CY, Liu Q, Huang QX, Liu JT, He YH, Lu J J, et al. (2013) Activation of PPARgamma is required for hydroxysafflor yellow A of Carthamus tinctorius to attenuate hepatic fibrosis induced by oxidative stress. Phytomedicine 20: 592-599. doi: 10.1016/j.phymed.2013.02.001 PMID: 23523101
27. Liu Q, Wang CY, Liu Z, Ma XS, He YH, Chen SS, et al. (2014) Hydroxysafflor yellow A suppresses liver fibrosis induced by carbon tetrachloride with high-fat diet by regulating PPAR-gamma/p38 MAPK signaling. Pharm Biol 52: 1085-1093. doi: 10.3109/13880209.2013.877491 PMID: 24618007
28. Li CC, Yang CZ, Li XM, Zhao XM, Zou Y, Fan L, et al. (2012) Hydroxysafflor yellow A induces apoptosis in activated hepatic stellate cells through ERK1/2 pathway in vitro. Eur J Pharm Sci 46: 397-404. doi: 10.1016/j.ejps.2012.03.003 PMID: 22449726
29. Dong H, Liu Y, Zou Y, Li C, Li L, Li, X, et al. (2013) Alteration of the ERK5 pathway by hydroxysafflor yellow A blocks expression of MEF2C in activated hepatic stellate cells in vitro: Potential treatment for hepatic fibrogenesis. Pharm Biol.
30. Li J, Zhang S, Lu M, Chen Z, Chen C, Han L, et al. (2013) Hydroxysafflor yellow A suppresses inflammatory responses of BV2 microglia after oxygen-glucose deprivation. Neurosci Lett 535: 51-56. doi: 10.1016/j.neulet.2012.12.056 PMID: 23333598
31. Jiang S, Shi Z, Li C, Ma C, Bai X, Wang C, et al. (2014) Hydroxysafflor yellow A attenuates ischemia/reperfusion-induced liver injury by suppressing macrophage activation. Int J Clin Exp Pathol 7: 2595-2608. PMID: 24966974
32. Cardinal J, Pan P, Dhupar R, Ross M, Nakao A, Lotze M, et al. (2009) Cisplatin prevents high mobility group box 1 release and is protective in a murine model of hepatic ischemia/reperfusion injury. Hepatology 50: 565-574. doi: 10.1002/hep.23021 PMID: 19492424
33. Sakai N, Van Sweringen HL, Schuster R, Blanchard J, Burns JM, Tevar AD, et al. (2012) Receptor activator of nuclear factor-kappaB ligand (RANKL) protects against hepatic ischemia/reperfusion injury in mice. Hepatology 55: 888-897. doi: 10.1002/hep.24756 PMID: 22031462
34. Yu HC, Qin HY, He F, Wang L, Fu W, Liu D, et al. (2011) Canonical notch pathway protects hepatocytes from ischemia/reperfusion injury in mice by repressing reactive oxygen species production through JAK2/STAT3 signaling. Hepatology 54: 979-988. doi: 10.1002/hep.24469 PMID: 21633967
35. Llacuna L, Barcena C, Bellido-Martin L, Fernandez L, Stefanovic M, Mari M, et al. (2010) Growth arrestspecific protein 6 is hepatoprotective against murine ischemia/reperfusion injury. Hepatology 52: 1371-1379. doi: 10.1002/hep.23833 PMID: 20730776
36. Yu W, Gwinn M, Clyne M, Yesupriya A, Khoury MJ (2008) A navigator for human genome epidemiology. Nat Genet 40: 124-125. doi: 10.1038/ng0208-124 PMID: 18227866
37. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, et al. (2009) Human Protein Reference Database - 2009 update. Nucleic Acids Res 37: D767-772. doi: 10.1093/nar/gkn892 PMID: 18988627
38. Wu L, Li X, Yang J, Liu Y, Fan X, Cheng Y, et al. (2013) CHD@ZJU: a knowledgebase providing network-based research platform on coronary heart disease. Database (Oxford) 2013: bat047.
39. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504. PMID: 14597658
40. Hopkins AL (2007) Network pharmacology. Nat Biotechnol 25: 1110-1111. PMID: 17921993
41. Hopkins AL (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4: 682-690. doi: 10.1038/nchembio.118 PMID: 18936753
42. Barone S, Okaya T, Rudich S, Petrovic S, Tenrani K, Wang Z, et al. (2005) Distinct and sequential upregulation of genes regulating cell growth and cell cycle progression during hepatic ischemia-reperfusion injury. Am J Physiol Cell Physiol 289: C826-835. PMID: 15888550
43. Tsutsui H, Nishiguchi S (2014) Importance of Kupffer cells in the development of acute liver injuries in mice. Int J Mol Sci 15: 7711-7730. doi: 10.3390/ijms15057711 PMID: 24802875
44. Taniai H, Hines IN, Bharwani S, Maloney RE, Nimura Y, Gao B, et al. (2004) Susceptibility of murine periportal hepatocytes to hypoxia-reoxygenation: role for NO and Kupffer cell-derived oxidants. Hepatology 39: 1544-1552. PMID: 15185295
45. Ogura Y, Sutterwala FS, Flavell RA (2006) The inflammasome: first line of the immune response to cell stress. Cell 126: 659-662. PMID: 16923387
46. Zhu P, Duan L, Chen J, Xiong A, Xu Q, Zhang H, et al. (2011) Gene silencing of NALP3 protects against liver ischemia-reperfusion injury in mice. Hum Gene Ther 22: 853-864. doi: 10.1089/hum.2010.145 PMID: 21128730
47. Wree A, Eguchi A, McGeough MD, Pena CA, Johnson CD, Canbay, A, et al. (2013) NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation and fibrosis. Hepatology.
48. Kamo N, Ke B, Ghaffari AA, Shen XD, Busuttil RW, Cheng G, et al. (2013) ASC/caspase-1/IL-1beta signaling triggers inflammatory responses by promoting HMGB1 induction in liver ischemia/reperfusion injury. Hepatology 58: 351-362. doi: 10.1002/hep.26320 PMID: 23408710
49. Kim HJ, Lee DW, Ravichandran K, D OK, Akcay A, Nguyen Q, et al. (2013) NLRP3 inflammasome knockout mice are protected against ischemic but not cisplatin-induced acute kidney injury. J Pharmacol Exp Ther 346: 465-472. doi: 10.1124/jpet.113.205732 PMID: 23833276
50. Kato A, Gabay C, Okaya T, Lentsch AB (2002) Specific role of interleukin-1 in hepatic neutrophil recruitment after ischemia/reperfusion. Am J Pathol 161: 1797-1803. PMID: 12414526
51. Serafin A, Rosello-Catafau J, Prats N, Gelpi E, Rodes J, Peralta C, et al. (2004) Ischemic preconditioning affects interleukin release in fatty livers of rats undergoing ischemia/reperfusion. Hepatology 39: 688-698. PMID: 14999687
52. Lutz A, Sanwald J, Thomas M, Feuer R, Sawodny O, Ederer M, et al. (2014) Interleukin-1beta enhances FasL-induced caspase-3/-7 activity without increasing apoptosis in primary mouse hepatocytes. PLoS One 9: e115603. doi: 10.1371/journal.pone.0115603 PMID: 25551609
53. Takehara T, Hayashi N, Tatsumi T, Kanto T, Mita E, Sasaki Y, et al. (1999) Interleukin 1beta protects mice from Fas-mediated hepatocyte apoptosis and death. Gastroenterology 117: 661-668. PMID: 10464143
54. Huang H, Ji L, Song S, Wang J, Wei N, Jiang M, et al. (2011) Identification of the major constituents in Xuebijing injection by HPLC-ESI-MS. Phytochem Anal 22: 330-338. doi: 10.1002/pca.1284 PMID: 21500296
55. Gong BL, Zhang Y, Xu QX, Chen YQ (2010) [The DNA binding activity of nuclear factor-KappaB in patients with severe pneumonia and the intervention effects of Xuebijing injection]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 22: 543-546. PMID: 20854735